Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 298

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 16F
Chunk 298
---
Item 16F. Change in Registrant’s Certifying Accountant.

The term of office of Odycé Nexia SAS, former joint principal statutory auditor of the Company, expired following the general meeting of shareholders of May 23, 2024. The report of Odycé Nexia SAS on the consolidated financial statements for each of the years ended December 31, 2023 and 2022 was conducted for French law purposes only. Odycé Nexia SAS is not a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB), and therefore did not conduct its audits in accordance with the standards of the PCAOB and was not engaged as the principal accountant to audit the registrant’s financial statements for such purposes.

The general meeting of shareholders appointed PricewaterhouseCoopers Audit as new Statutory Auditor to replace Odycé Nexia SAS, and to act as joint principal statutory auditor to audit the Company’s financial statements in accordance with the standards of the PCAOB. Consequently, the Supervisory Board proposed to the general meeting of shareholders of May 23, 2024 to appoint PricewaterhouseCoopers Audit as joint principal statutory auditor for a 6-year term, i. e. until the general meeting of shareholders to be held in 2030, which will approve the financial statements for the year 2029.

Furthermore, for the years ending on December 31, 2022 and 2023 and the subsequent interim period through May 23, 2024, we had not consulted with PricewaterhouseCoopers Audit regarding either (1) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to our consolidated financial statements, and neither a written report was provided to Innate Pharma or oral advice was provided that PricewaterhouseCoopers Audit concluded was an important factor considered by Innate Pharma in reaching a decision as to the accounting, auditing or financial reporting issue; or (2) any matter that was the subject of a disagreement or a reportable event.

The selection procedure of PricewaterhouseCoopers Audit was overseen by the Audit Committee, following which a recommendation to the Supervisory Board was issued.

Item 16G. Corporate Governance.